triazoles has been researched along with Diabetic Angiopathies in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basha, FZ; Choudhary, MI; Iqbal, S; Jahan, H; Pizzi, M; Shaikh, S; Siddiqui, NN | 1 |
| Andersson, C; Mogensen, UM; Scheller, NM; Torp-Pedersen, C; Vaag, A | 1 |
| Cappuccio, F; Ceriello, A; Genovese, S; Schnell, O; Standl, E; Valensi, P | 1 |
| Bando, YK; Ishizu, T; Kodama, K; Murohara, T; Node, K; Oyama, J; Sato, Y | 1 |
| Eurich, DT; McAlister, FA; Minhas-Sandhu, JK; Senthilselvan, A; Weir, DL | 1 |
| Bhatt, DL; Cavender, MA | 1 |
| Fonseca, VA; John-Kalarickal, J; Wani, JH | 1 |
| Akiyama, E; Fujisue, K; Hokimoto, S; Iwashita, S; Jinnouchi, H; Kaikita, K; Kurokawa, H; Maeda, H; Matsubara, J; Ogawa, H; Ohba, K; Sugiyama, S; Yamamoto, E | 1 |
| Satoh, K | 1 |
2 review(s) available for triazoles and Diabetic Angiopathies
| Article | Year |
|---|---|
Type 1 diabetes and cardiovascular disease.
Topics: Antihypertensive Agents; Autonomic Nervous System Diseases; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diabetic Neuropathies; Drug Therapy, Combination; Exenatide; Exercise Therapy; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Insulin; Oxidative Stress; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
1 trial(s) available for triazoles and Diabetic Angiopathies
| Article | Year |
|---|---|
Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study.
Topics: Adult; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Prospective Studies; Pyrazines; Research Design; Sitagliptin Phosphate; Triazoles | 2014 |
7 other study(ies) available for triazoles and Diabetic Angiopathies
| Article | Year |
|---|---|
Suppression of COX-2/PGE
Topics: Carbazoles; Cyclooxygenase 2; Diabetic Angiopathies; Dinoprostone; Glucose; Glycation End Products, Advanced; Humans; Monocytes; NF-kappa B; Pyruvaldehyde; Reactive Oxygen Species; Signal Transduction; Triazoles | 2022 |
All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
Topics: Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Stroke; Treatment Outcome; Triazoles | 2014 |
Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Pyrazines; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Humans; Male; Pyrazines; Triazoles | 2014 |
Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.
Topics: Aged; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Chi-Square Distribution; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Inflammation Mediators; Linear Models; Logistic Models; Male; Manometry; Middle Aged; Multivariate Analysis; Odds Ratio; Peripheral Arterial Disease; Pyrazines; Risk Factors; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2013 |
Dipeptidyl peptidase-4 inhibitors--emerging player for vascular protection.
Topics: Anti-Inflammatory Agents; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Humans; Male; Peripheral Arterial Disease; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
New medications help those with diabetes avoid heart trouble. Drugs mimic the body's natural insulin and glucose controls, but diet and exercise are still keys to controlling the disease.
Topics: Diabetes Mellitus; Diabetic Angiopathies; Exenatide; Heart Diseases; Humans; Hypoglycemic Agents; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2007 |